author-photo

Xiaoli S. Glasgow

Merck & Co.

5

Papers

69

Citations

Citation Trend

Filter By

Papers (4) Sort By

Journal Conference Others

Effect of tildrakizumab (MK‐3222), a high affinity, selective anti‐IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis

2018 British Journal of Clinical Pharmacology
Show All
- Source
- Cite
- Save
Citations (20)
A Thorough QTc Study Confirms Early Pharmacokinetics/QTc Modeling: A Supratherapeutic Dose of Omarigliptin, a Once‐Weekly DPP‐4 Inhibitor, Does Not Prolong the QTc Interval

2016 Clinical pharmacology in drug development
Show All
- Source
- Cite
- Save
Citations (11)
Pharmacokinetics and Pharmacodynamics of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitor, after Single and Multiple Doses in Healthy Subjects.

2016 The Journal of Clinical Pharmacology
Show All
- Source
- Cite
- Save
Citations (20)
Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes Mellitus.

2016 Clinical Therapeutics
Show All
- Source
- Cite
- Save
Citations (14)